Pedmark (sodium thiosulfate injection)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Pedmark (sodium thiosulfate injection) for intravenous use

APPROVAL CRITERIA

Requests for Pedmark (sodium thiosulfate injection) may be approved if the following criteria are met:

I. Individual has a diagnosis of localized, non-metastatic solid tumor; **AND**
II. Individual is using to reduce the risk of ototoxicity associated with cisplatin; **AND**
III. Pedmark will be administered starting 6 hours after completion of cisplatin infusion, OR for multiday cisplatin regimens, Pedmark will be administered 6 hours after each cisplatin infusion but at least 10 hours before the next cisplatin infusion; **AND**
IV. Individual has a baseline serum sodium less than 145 mmol/L; **AND**
V. Individual is 1 month of age or older;

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2022. URL: http://www.clinicalpharmacology.com. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: April 5, 2022.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.